First-ever brain chemistry database will allow clinicians to quickly infer brain biomarker data to support the diagnostic process in conditions such as Alzheimer's Disease
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
Azelis will be the exclusive distributor for inulin, oligofructose, scFOS, texturized wheat proteins, faba beans, Beta-glucans, meatless solution
Evinova will operate as a separate health-tech business within AstraZeneca
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ
Phase 3 data expected in the second half of 2024
Subscribe To Our Newsletter & Stay Updated
